Seattle Genetics, Inc. (SGEN)
(Delayed Data from NSDQ)
$67.25 USD
+0.33 (0.49%)
Updated May 3, 2019 04:00 PM ET
After-Market: $67.27 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$67.25 USD
+0.33 (0.49%)
Updated May 3, 2019 04:00 PM ET
After-Market: $67.27 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Biotech Stock Roundup: PTGX Down, VRNA Up, AMGN's Repatha Gets Positive Opinion
by Zacks Equity Research
The biotech sector was in focus last week with Protagonist's stock plunging on news of discontinuation of a phase IIb study and Verona Pharma stock surging on positive top-line data from COPD study among others.
Seattle Genetics' Adcetris Gets FDA Nod for Label Expansion
by Zacks Equity Research
Seattle Genetics' (SGEN) cancer drug, Adcetris, gets FDA approval to include fifth indication, frontline treatment of advanced classical Hodgkin lymphoma, in its label.
Seattle Genetics (SGEN) Up 8.4% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Seattle Genetics (SGEN) Q4 Earnings & Revenues Top Estimates
by Zacks Equity Research
Seattle Genetics (SGEN) beats estimates on both counts on the back of strong Adcetris sales.
Why Earnings Season Could Be Great for Seattle Genetics (SGEN)
by Zacks Equity Research
Seattle Genetics (SGEN) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Seattle Genetics Adcetris Performs Well Despite Competition
by Zacks Equity Research
Seattle Genetics (SGEN) is witnessing robust growth for its sole marketed product, Adcetris. However, over dependence on the same is a concern amid rising competition.
Seattle Genetics' Adcetris Gets EU Nod for Label Expansion
by Zacks Equity Research
European Commission extend the current conditional marketing authorization for an expanded indication of Adectris of Seattle Genetics (SGEN) and partner Takeda.
Seattle Genetics' Adcetris sBLA Gets FDA Priority Review
by Zacks Equity Research
Seattle Genetics' supplemental Biologics License Application for the label expansion of its lymphoma drug, Adcetris, was accepted by the FDA and granted priority review.
Why Is Seattle Genetics (SGEN) Down 4.1% Since the Last Earnings Report?
by Zacks Equity Research
Seattle Genetics (SGEN) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Seattle Genetics' Adcetris Gets FDA Nod for Label Expansion
by Zacks Equity Research
Seattle Genetics received an approval from the FDA for an expanded indication of its drug Adcetris a month before its action date.
Seattle Genetics (SGEN) Loss Narrows in Q3, Revenues Beat
by Zacks Equity Research
Seattle Genetics (SGEN) reported narrower-than-estimated loss in the third quarter. Moreover, including a warrant exercise it turned profitable. The shares were up in response.
Is a Beat in Store for Agenus (AGEN) This Earnings Season?
by Zacks Equity Research
Agenus (AGEN) is expected to report third-quarter 2017 on Oct 26.
Should You Sell Seattle Genetics (SGEN) Before Earnings?
by Soumic Nandy
Seattle Genetics (SGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP ahead of earnings.
Is a Beat in Store for Alexion (ALXN) This Earnings Season?
by Zacks Equity Research
Alexion's (ALXN) blockbuster drug, Soliris, continues to perform well and the company is scheduled to report third-quarter 2017 results on Oct 26, before the opening bell.
Seattle Genetics Inks Clinical Collaborations for Cancer Drug
by Zacks Equity Research
Seattle Genetics (SGEN) announced two clinical collaborations to evaluate SGN-LIV1A in triple negative breast cancer.
Seattle Genetics Begins Phase II Study of Cancer Candidate
by Zacks Equity Research
Seattle Genetics (SGEN) and Astellas Pharma initiate phase II study-EV-201 of enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer.
Cancer Space Last Week Update: Pipeline Expansion in Focus
by Zacks Equity Research
Last week, a few companies in the cancer segment entered deals for expanding their portfolio. Another key development was a ruling in favor of a major cancer drug by the U.S. patent office.
Company News For Oct 3, 2017
by Zacks Equity Research
companies in the news are: CALM, GE, SGEN, TSM
Seattle Genetics' Adcetris Gets Breakthrough Therapy Status
by Zacks Equity Research
Seattle Genetics' (SGEN) lymphoma drug, Adcetris has been granted Breakthrough Therapy Designation by the FDA for treating patients with advanced classical Hodgkin lymphoma with no prior treatments.
Seattle Genetics (SGEN) in Focus: Stock Moves 7.9% Higher
by Zacks Equity Research
Seattle Genetics (SGEN) was a big mover last session, as the company saw its shares rise nearly 8% on the day amid huge volumes.
Bristol-Myers (BMY) Opdivo Gets Approval for Liver Cancer
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced that the FDA has approved immuno-oncology drug Opdivo for liver cancer.
Bristol-Myers' Opdivo Study Meets Early Success, Stock Up
by Zacks Equity Research
Bristol-Myers' (BMY) phase III study evaluating Opdivo plus Yervoy successfully met its co-primary endpoints and thus was stopped earlier than expected.
Pfizer's Acute Leukemia Drug Mylotarg Approved by the FDA
by Zacks Equity Research
Pfizer's (PFE) Mylotarg received FDA nod as a treatment for new or relapsed CD33-positive acute myeloid leukemia.
Seattle Genetics' Adcetris Granted Priority Review by FDA
by Zacks Equity Research
Seattle Genetics, Inc.'s (SGEN) supplemental Biologics License Application for Adcetris in patients with cutaneous T-cell lymphoma has been accepted by the FDA and granted priority review.
Seattle Genetics (SGEN) Q2 Loss Narrower than Expected
by Zacks Equity Research
Seattle Genetics (SGEN) incurred narrower-than-expected loss in Q2 and provided an encouraging guidance for Adcetris.